1. Home
  2. AMPL vs MESO Comparison

AMPL vs MESO Comparison

Compare AMPL & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMPL
  • MESO
  • Stock Information
  • Founded
  • AMPL 2012
  • MESO 2004
  • Country
  • AMPL United States
  • MESO Australia
  • Employees
  • AMPL N/A
  • MESO N/A
  • Industry
  • AMPL EDP Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AMPL Technology
  • MESO Health Care
  • Exchange
  • AMPL Nasdaq
  • MESO Nasdaq
  • Market Cap
  • AMPL 1.4B
  • MESO 1.2B
  • IPO Year
  • AMPL 2021
  • MESO N/A
  • Fundamental
  • Price
  • AMPL $11.83
  • MESO $13.17
  • Analyst Decision
  • AMPL Hold
  • MESO Strong Buy
  • Analyst Count
  • AMPL 7
  • MESO 4
  • Target Price
  • AMPL $11.00
  • MESO $11.50
  • AVG Volume (30 Days)
  • AMPL 370.7K
  • MESO 238.9K
  • Earning Date
  • AMPL 11-07-2024
  • MESO 08-28-2024
  • Dividend Yield
  • AMPL N/A
  • MESO N/A
  • EPS Growth
  • AMPL N/A
  • MESO N/A
  • EPS
  • AMPL N/A
  • MESO N/A
  • Revenue
  • AMPL $292,544,000.00
  • MESO $5,902,000.00
  • Revenue This Year
  • AMPL $9.96
  • MESO $66.05
  • Revenue Next Year
  • AMPL $7.75
  • MESO $348.27
  • P/E Ratio
  • AMPL N/A
  • MESO N/A
  • Revenue Growth
  • AMPL 8.29
  • MESO N/A
  • 52 Week Low
  • AMPL $7.37
  • MESO $1.61
  • 52 Week High
  • AMPL $14.42
  • MESO $12.70
  • Technical
  • Relative Strength Index (RSI)
  • AMPL 64.68
  • MESO 67.62
  • Support Level
  • AMPL $11.41
  • MESO $10.30
  • Resistance Level
  • AMPL $11.91
  • MESO $11.59
  • Average True Range (ATR)
  • AMPL 0.42
  • MESO 0.50
  • MACD
  • AMPL 0.02
  • MESO 0.10
  • Stochastic Oscillator
  • AMPL 77.72
  • MESO 77.98

About AMPL Amplitude Inc.

Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.

About MESO Mesoblast Limited

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.

Share on Social Networks: